Home > Insider Trading > Filing (0001209191-18-054513)

Filing Details

Accession Number:: 0001209191-18-054513
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-10-09 16:09:34
Reporting Period:: 2018-10-05

Accepted Time:: 2018-10-09 16:09:34
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1439222	Agios Pharmaceuticals Inc	AGIO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1581956	Scott Biller	C/O Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge MA 02139	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-10-05	3,000	$9.05	53,932	No	4	M	Direct
Common Stock	Disposition	2018-10-05	900	$68.56	53,032	No	4	S	Direct
Common Stock	Disposition	2018-10-05	979	$69.47	52,053	No	4	S	Direct
Common Stock	Disposition	2018-10-05	1,100	$71.05	50,953	No	4	S	Direct
Common Stock	Disposition	2018-10-05	21	$71.77	50,932	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock options (right to buy)	Disposition	2018-10-05	3,000	$0.00	3,000	$9.05

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
7,154		2023-04-30	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	6,264	Indirect	See footnote

Footnotes

This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $68.13 to $69.05. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $69.24 to $70.22. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $70.61 to $71.37. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Shares held by a spousal lifetime access trust, of which the reporting person's wife is trustee.
This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares.